Thu, Dec 18, 2014, 7:56 AM EST - U.S. Markets open in 1 hr 34 mins

Recent

% | $
Quotes you view appear here for quick access.

Dendreon Corporation Message Board

  • anderbest18 anderbest18 May 8, 2010 6:13 AM Flag

    AEZS! YOUR NEXT 'DNDN'-PLAY!

    - 50 Million cash on hand. Total $10 billion sales potential.

    -CANCER VACCINE: AEZS-120 cancer vaccine similar to Dendreon’s provenge. Phase I to begin mid-to-end 2010

    -PHASE 3 TRIALS: 4 Phase 3 cancer trials in 2010:

    1) AEZS-130 (SolorelTM) Diagnostic Adult Growth Hormone Deficiency trial. Filing of U.S. NDA planned after study completed later this year.
    2) Perifosine, Multiple myeloma Cancer.
    3) Perifosine, Refractory Advanced Colorectal.
    4) AEZS-108, Ovarian Cancer.

    AEZS could initiate also Perifosine phase III for treatment of Kidney Cancer. That would make it FIVE phase III cancer trials.

    -PENDING PHASE 2 RESULTS (JUNE ASCO MEETING):
    Final results of a randomized phase II study of perifosine in combination with capecitabine (P-CAP) versus placebo plus capecitabine (CAP) in patients (pts) with second- or third-line metastatic colorectal cancer (mCRC) are to be Presented by Donald Richards.

    PARTNERS: AEterna stated publicly they are looking for partners, news could come at any time.

    AEZS pipeline:
    Perifosine (phase III/KERX partner)
    Multiple Myeloma
    Advanced Colorectal Cancer
    Kidney Cancer and Others
    AEZS-108 (phase II)
    Endometrial Cancer
    Ovarian Cancer
    Other Cancers
    AEZS-112 (phase I)
    Solid Tumor
    AEZS-120 *Tumor Vaccine (pre-clinical **hello DNDN)
    Prostate Cancer
    AEZS-129/131PI3K/ErkInhibitor (pre-clinical)
    Oncology
    Cetrotide®
    (Marketed by Merck Serono, Nippon Kayaku / Shionogi (Japan))
    In VitroFertilization
    AEZS-130 (SolorelTM) - Phase III
    Diagnostic –Adult Growth Hormone Deficiency
    AEZS-130 (macimorelin) - Phase I
    Therapeutic
    AEZS-123Ghrelin Antagonist - Preclinical

    SortNewest  |  Oldest  |  Most Replied Expand all replies
 
DNDN
0.127+0.013(+10.08%)Nov 18 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.